Key Drug Patent Expirations in 2026 (U.S. and Global):

Diabetes/Metabolic:
Januvia (sitagliptin) & Janumet (Merck): Major market loss expected in 2026.
Semaglutide (Ozempic/Wegovy) (Novo Nordisk): Patent expiration in 2026 for markets including India, China, and Canada.

Cardiovascular/Thrombotic:
Eliquis (apixaban) (BMS/Pfizer): Original patent extends to November 2026, with generics likely to follow quickly.
Xarelto (rivaroxaban) (Janssen): Patents expiring around 2026.
Immunology/Chronic Disease:
Xeljanz (tofacitinib) (Pfizer): Patent protection lapses, opening up the rheumatoid arthritis market.
Eylea (aflibercept) (Regeneron): Specific formulations facing competition, though some protection extends into 2027.

Oncology/Other:
Sprycel (dasatinib) (BMS): Patent expiry anticipated in September 2026.
Zelboraf (vemurafenib) (Roche): Mid-2026 expiration.
Gilotrif (afatinib) (Boehringer Ingelheim): July 2026 expiration.
Rexulti (brexpiprazole) (Otsuka): April 2026.
Trintellix (vortioxetine) (Lundbeck/Takeda): June 2026.

Impact and Context:

Generics Surge: The 2026 patent cliff is particularly heavy on high-revenue blockbuster drugs, allowing manufacturers like Dr. Reddy's and Sandoz to enter with generics.

International Variations: While generic semaglutide could enter Canada early in 2026, specific patent litigation may delay, alter, or expedite entry in other regions.

"Junk" Patents: The FTC is actively challenging over 300 patent listings for drugs, including those for diabetes, to prevent artificial delays in competition.

+++++++++++++++++++++++++++++++++++

Key point: Having cheaper Ozempic, etc NOW is no big deal. The patent EXPIRES THIS YEAR.

So why did NOT the insurance companies "GO FOR IT"? How much was paid to Spankee? DOPE ?